OpenAI acquires Orchestra Bio to accelerate drug development with AI
OpenAI acquires Orchestra Bio to integrate AI-powered operations into life sciences R&D, aiming to speed up drug development.
Novo Nordisk
Latest Novo Nordisk coverage.
Anthropic's $400M biotech buyout fuels AI drug discovery push
Anthropic acquires Coefficient Bio for $400M, partnering with Novo Nordisk and Bristol Myers Squibb to accelerate AI-driven drug discovery.
Novo Nordisk partners with Anthropic to accelerate AI-driven drug discovery
Novo Nordisk and Anthropic team up to speed up drug development using AI, aiming to advance Novo's position in the field.